...
首页> 外文期刊>Cancer gene therapy >Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer
【24h】

Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer

机译:siRNA沉默hdm2癌基因抑制p53依赖性人类乳腺癌

获取原文
   

获取外文期刊封面封底 >>

       

摘要

RNA interference technology is a powerful tool for silencing endogenous or exogenous genes in mammalian cells. Here our results showed that hdm2-siRNA silenced its target mRNA specifically and effectively in human breast cancer cells, reduced tumor cell proliferation and induced apoptotic cell death. Other molecular features modified by hdm2-siRNA included decreased Bcl-2, NF-B, survivin, Ras and Raf levels, elevated p53, p21, BRCA1, Bax, and caspase levels as well as altered expression of other genes. hdm2-siRNA also caused cell cycle arrest at G1 phases with reduction in cyclin and Cdk proteins. In addition, hdm2-siRNA displayed in vivo antitumor activity and increased therapeutic effectiveness of mitomycin in MCF-7 xenografts. Thus, hdm2-siRNA may be a promising gene-specific drug for the treatment of human breast cancer and other tumors.
机译:RNA干扰技术是沉默哺乳动物细胞内源或外源基因的强大工具。在这里,我们的结果表明,hdm2-siRNA在人乳腺癌细胞中特异性且有效地沉默了其靶mRNA,降低了肿瘤细胞的增殖并诱导了凋亡性细胞死亡。 hdm2-siRNA修饰的其他分子特征包括Bcl-2,NF-B,survivin,Ras和Raf水平降低,p53,p21,BRCA1,Bax和caspase水平升高以及其他基因表达改变。 hdm2-siRNA还导致细胞周期停滞在G1期,细胞周期蛋白和Cdk蛋白减少。此外,hdm2-siRNA在MCF-7异种移植物中显示出体内抗肿瘤活性并提高了丝裂霉素的治疗效果。因此,hdm2-siRNA可能是一种有前途的基因特异性药物,可用于治疗人类乳腺癌和其他肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号